According to the recent research, there are over 80% of people would be motivated to exercise if incentivized by crypto...


Recent Study Reveals That Crypto Motivates People to Exercise

On Friday, Prime Minister Ranil Wickremesinghe warned of a food shortage as the island nation battles a devastating economic...


Thousands queue for petrol, gas in Sri Lanka amid warnings of food shortages

ASML, a semiconductor industry and stock market giant, might have to think smaller. Or maybe bigger. Currently, it is building machines...


Computer chip giant ASML places big bets on a tiny future

Finance ministers and central bank governors of the United States, Japan, Canada, Britain, Germany, France and Italy - the G7, agreed on...


Money for Ukraine Priority in G7 Agenda; Inflation, Food a Concern

An auto safety agency in the U.S. said on Wednesday that it has opened an investigation into a fatal crash involving a Tesla...

Stock Markets

U.S. Agency opens investigation involving Tesla due to 14 Crash Deaths


27 Jan 2022

Moderna Commences Trial for Potential Omicron Booster Shot

Moderna Commences Trial for Potential Omicron Booster Shot

The Index Today

Moderna Inc. on Wednesday announced that it has begun testing a potential booster vaccine specifically aimed at tackling the Omicron variant of COVID-19. This comes after Pfizer started similar vaccine trials to protect against the highly contagious variant.

Although the Omicron is a comparatively milder version of the coronavirus, it has been spreading rapidly leading to mounting infection rates that increase pressure on the healthcare systems across the world. At the moment, 99.9% cases of COVID-19 are reported to be Omicron-related.

Moderna is planning on running the study on 300 participants aged 18 years and above who will be divided into two groups. The test would be conducted on individuals who have received just two doses of its primary mRNA-1273 vaccine.

This comes as three separate studies conducted by the Centers for Disease Control and Prevention (CDC) in the U.S. found that a third dose of the mRNA vaccine by either Moderna or Pfizer is essential in protecting against the Omicron.

©Photo: Bodo Schackow/dpa via AP